Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Jan 21, 2021 11:56am
154 Views
Post# 32345344

Deal Or No Deal

Deal Or No DealLet's review the Twitter trail:

Nov. 10th
Mainpointe Binding Agreement Deal announced.

Nov. 11th
"Posted the largest 30 day % gain..."

Nov. 13th
"We look forward to sealing deal with Mainpointe....before year-end...."

Nov. 30th
"Based on how little red text...we are bullish on our chances this deal closes with plenty of days left in 2020."

Dec. 8th
"Christmas is coming but we believe a signed deal with Mainpointe is coming even sooner."

Dec. 24th
"We don't have the Mainpointe deal sitting under the tree but the wrapping is almost done...We can't imagine it's not part of our New Years celebration."

Jan. 7th
"All is going smoothly in the last stages of getting the Replicel - Mainpointe deal to signature. Some last minute due diligence items being cleared up."

Jan. 18th
" We'r very excited to get to work on the next stage of Replicel's product development program. Once this deal closes, we are ready to rock. This is what we live for. 


Wiating for the next Twitter installment.  Many things I could say here but I don't think it's necessary.



<< Previous
Bullboard Posts
Next >>